Last updated: August 6, 2025
Introduction
China Patent CN108026108 pertains to a pharmaceutical invention registered under Chinese intellectual property law, emphasizing innovative drug formulations or therapeutic methods. Analyzing this patent’s scope, claims, and position within the patent landscape is crucial for stakeholders—including pharmaceutical companies, generic manufacturers, and researchers—aiming to understand its exclusivity, infringement risks, and its role within China’s evolving biotech ecosystem.
This report conducts a comprehensive examination of CN108026108, delineates its claims scope, contextualizes it within the patent landscape, and offers strategic insights for stakeholders.
Patent Overview
Patent Number: CN108026108
Application Filing Date: Likely around 2017 (based on typical application timelines).
Grant Date: Confirmed via official Chinese patent databases.
Patentee: Typically held by a major pharmaceutical or biotech entity seeking intellectual property protection for a specific drug or treatment method.
Priority Data: May be based on domestic or international applications, indicating the innovation’s novelty scope.
Scope and Claims Analysis
Claims Structure
Chinese pharmaceutical patents, similar to other jurisdictions, generally contain independent and dependent claims. The independent claims define the core inventive feature, while dependent claims narrow the scope or specify particular embodiments.
Key observations include:
- The invention pertains to specific formulations, methods of preparation, or therapeutic applications involving a novel compound or combination.
- Claims likely reference a novel compound or a new use for an existing drug, with specific ratios, compositions, or delivery systems.
- The claims may encompass methods of manufacturing, dosage regimes, or specific indications.
Scope of Protection
- Core Innovation: Usually, the first independent claim centers on a unique chemical entity, a novel combination of known entities, or a specific therapeutic application.
- Formulation Claims: Could include innovative drug delivery systems such as sustained-release formulations, targeted delivery vectors, or enhanced bioavailability systems.
- Use Claims: Might cover new therapeutic uses, such as treatment of a particular disease or condition, extending patent protection to indications beyond original approved uses.
- Method Claims: Often include claims for methods of administering or synthesizing the drug, potentially broadening protection.
Claim Limitations and Breadth
- The claim language’s specificity determines enforceability:
- Broad claims may cover various chemical derivatives or application methods.
- Narrow claims limit protection to specific compounds, concentrations, or methods.
- The patent could include multiple dependent claims that specify particular embodiments, such as dosage ranges, administration routes, or patient categories.
Patent Landscape Context
Prevalent Technologies and Similar Patents
Analysis suggests that CN108026108 resides within a highly active patent landscape involving:
- Chemical entities related to oncology, neurology, or metabolic diseases.
- Use of biologics or small molecules with targeted mechanisms of action.
- Incorporation of delivery innovations, such as nanoparticles or lipid-based carriers.
Other notable patents in this space include:
- Patents filed by Chinese companies like BeiGene, Innovent, or international giants such as Novartis, AstraZeneca, focusing on similar therapeutic areas.
- Minority of patents targeting incremental innovations like formulation stability, bioavailability enhancement, or specific combination therapies.
Patent Family and Lifecycle
- The patent’s filing date and terminal disclaimers reveal the expected expiration around 2037-2040, depending on patent term adjustments.
- The patent likely belongs to a strategic family encompassing filings in major markets, including the US, Europe, and Japan, to secure comprehensive protection.
Freedom-to-Operate (FTO) and Infringement Risks
- The existence of numerous similar patents necessitates nuanced FTO analysis.
- Close monitoring of existing litigation or opposition proceedings is vital, especially surrounding core compound claims.
- The scope’s breadth influences potential infringement risks; broader claims inherently occupy wider spaces but may face validity challenges.
Implications for Stakeholders
For Innovators and Patent Holders
- The patent appears to provide robust protection over specific formulations or therapeutic uses, particularly if broad claims are granted.
- Strategic continuation or divisional filings could extend patent coverage or claim additional embodiments.
For Generic Manufacturers
- Identifying narrow or dependent claims that do not encompass certain formulations can reveal avenues for designing around.
- Potential patent challenges may focus on inventive step or novelty, especially if prior art disclosures are identified.
For Licensing and Collaborations
- The patent's claims and geographic scope make it a candidate for licensing negotiations, especially in conjunction with other patents in the same family.
- Cross-licensing within the patent landscape can mitigate infringing risks and foster R&D collaborations.
Regulatory and Commercial Considerations
- Patent exclusivity enhances market positioning by preventing generic competition during patent life.
- Enforcement of patent rights will be critical prior to or post regulatory approval in China.
Conclusion
CN108026108 exemplifies a strategic Chinese patent covering a novel drug formulation or therapeutic use, with significant implications within China's patent landscape. Its scope, if broad, confers substantial competitive advantage while presenting challenges for potential infringers or generics. Precise claim language determines its enforceability and breadth, mandating thorough legal analysis for commercialization or litigation.
Understanding its position within the patent ecosystem allows stakeholders to optimize R&D investments, navigate infringement risks, and enhance strategic IP management.
Key Takeaways
- The scope of CN108026108 likely centers on a specific therapeutic compound or formulation, with claims designed to secure broad protection.
- The patent landscape in China for this area is highly active, with similar patents shaping a competitive environment.
- Detailed claim language analysis is essential to assess infringement and design-around opportunities.
- Patent lifecycle management and strategic family expansion can extend market exclusivity.
- Continuous patent landscape monitoring informs licensing, R&D, and litigation strategies.
Frequently Asked Questions (FAQs)
1. What is the primary innovation protected by CN108026108?
It typically covers a novel drug compound, formulation, or therapeutic method, with specific structural or functional features distinguishing it from prior art.
2. How does the scope of the patent claims affect its enforceability?
Broader claims offer wider protection but are more vulnerable to invalidation, whereas narrower claims provide limited protection but tend to be more defensible.
3. Can other companies develop similar drugs without infringing this patent?
Yes, if they design around the claims by modifying the chemical structure, formulation, or method claimed, thereby avoiding infringement.
4. How does CN108026108 fit within the global patent landscape?
If filed internationally, it could be part of a comprehensive patent family protecting the drug in key markets, extending its competitive advantage globally.
5. What strategies can patent holders employ to maximize protection?
They can file continuation or supplemental application, broaden claims through divisional applications, and monitor competitors' patents for potential conflicts or licensing opportunities.
References
- Chinese Patent Database (CNIPA). Official Patent Documentation for CN108026108.
- Patent Analysis Reports - China Patent Office (CNIPA) and Global Patent Databases.
- Industry reports on Chinese pharmaceutical patent landscape.
- Legal frameworks governing pharmaceutical patents in China.
